





Development of new drug Vonifimod for the treatment of Alopecia Areata

NEXTGEN Bioscience

Disease Area	Immunology
Product Type	Small molecule
Indication	1 st indication : Alopecia Areata 2 nd indication : Ulcerative colitis
Target	Sphingosine-1-phosphate receptor (S1PR) 1 and 4
Mechanism of Action	The functional antagonist of S1PR1 & 4 Vonifimod affects lymphocyte trafficking which leads to immune suppression
Competitiveness	<ol style="list-style-type: none"> 1. Selective towards S1P receptor subtypes associated with lymphocyte 2. Absence of off-target safety risk; No significant CV events or macular edema 3. Reduced risk of opportunistic infections due to relatively shorter half-life 4. No titration required 5. Rapid suppression of lymphocytes & recovery
Development Stage	Phase 2
Route of Administration	Oral Administration

- Vonifimod (NXC736) reduced the alopecia areata (AA) lesion area during 84 days (12 weeks) of oral administration in a mouse model.



Key Data

IP

Alopecia Areata - US, Korea, Australia, etc (Registered)